VRTX

Vertex Pharmaceuticals Incorporated NASDAQ

Healthcare ·Biotechnology ·US · vrtx.com

$423.92

After hrs $424.35 -1.28%

Mkt Cap $109.4B

52w Low $362.50 41.9% of range 52w High $509.00

50d MA $455.29 200d MA $436.61

P/E (TTM) 27.4x

EV/EBITDA 23.1x

P/B 5.8x

Debt/Equity 0.2x

ROE 21.2%

P/FCF 36.3x

RSI (14) —

ATR (14) —

Beta 0.37

50d MA $455.29

200d MA $436.61

Avg Volume 1.4M

About

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of a…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Feb 12, 2026	AMC	5.11	5.03	-1.6%	465.02	+1.4%	+5.7%	+2.6%	+1.1%	+0.9%	+2.6%	+0.2%	—
Nov 3, 2025	AMC	4.57	4.80	+5.0%	426.00	-1.7%	-1.0%	-2.1%	-2.3%	-3.9%	-1.1%	+8.7%	—
Aug 4, 2025	AMC	4.29	4.52	+5.4%	472.27	-13.6%	-20.6%	-18.3%	-20.5%	-22.4%	-20.7%	-16.0%	—
May 5, 2025	AMC	4.25	4.06	-4.5%	500.19	-6.9%	-10.0%	-13.1%	-14.1%	-15.0%	-12.2%	-10.9%	—
Feb 10, 2025	AMC	4.02	3.98	-1.0%	469.97	-2.2%	-3.1%	-3.6%	-1.6%	-2.3%	-1.7%	+5.4%	—
Nov 4, 2024	AMC	4.14	4.38	+5.8%	472.80	+2.2%	+5.7%	+4.4%	+6.3%	+9.3%	+6.1%	-1.9%	—
Aug 1, 2024	AMC	-11.63	-12.83	-10.3%	505.78	-2.8%	-2.2%	-5.7%	-6.2%	-7.9%	-7.9%	-5.9%	—
May 6, 2024	AMC	4.06	4.76	+17.2%	402.50	+1.0%	+1.9%	+4.1%	+4.1%	+5.0%	+6.8%	+20.0%	—
Feb 5, 2024	AMC	4.10	4.20	+2.4%	428.89	-0.0%	-3.0%	-2.3%	-1.4%	-1.4%	-2.4%	-4.0%	—
Nov 6, 2023	AMC	3.97	4.08	+2.8%	385.76	-2.2%	-1.9%	-2.3%	-4.5%	-3.1%	-1.8%	-8.4%	—
Aug 1, 2023	AMC	3.88	3.89	+0.3%	347.74	+0.6%	+3.1%	+0.0%	-2.1%	-0.7%	-0.9%	+0.2%	—
May 1, 2023	AMC	3.00	3.05	+1.7%	345.00	+0.0%	+0.3%	+0.4%	+0.5%	+0.9%	-0.3%	-6.2%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 30	Canaccord Genuity	Maintains	Hold → Hold	—	$423.24	$423.66	+0.1%	+1.0%	+0.2%	—	—	—
Apr 10	Morgan Stanley	Maintains	Overweight → Overweight	—	$446.78	$446.08	-0.2%	-2.4%	-1.5%	-0.6%	-1.1%	-2.5%
Mar 18	Maxim Group	Upgrade	Hold → Buy	—	$462.49	$462.80	+0.1%	-2.4%	-1.0%	-1.8%	-2.4%	-3.0%
Mar 11	Truist	Maintains	Buy → Buy	—	$499.17	$497.88	-0.3%	-1.4%	-4.2%	-6.0%	-6.6%	-7.3%
Mar 10	Morgan Stanley	Maintains	Overweight → Overweight	—	$460.87	$482.25	+4.6%	+8.3%	+6.8%	+3.7%	+1.8%	+1.1%
Mar 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$460.87	$482.25	+4.6%	+8.3%	+6.8%	+3.7%	+1.8%	+1.1%
Mar 10	Oppenheimer	Maintains	Outperform → Outperform	—	$460.87	$482.25	+4.6%	+8.3%	+6.8%	+3.7%	+1.8%	+1.1%
Mar 10	Citigroup	Maintains	Buy → Buy	—	$460.87	$482.25	+4.6%	+8.3%	+6.8%	+3.7%	+1.8%	+1.1%
Mar 10	BofA Securities	Maintains	Buy → Buy	—	$460.87	$482.25	+4.6%	+8.3%	+6.8%	+3.7%	+1.8%	+1.1%
Feb 17	Barclays	Maintains	Overweight → Overweight	—	$491.47	$489.46	-0.4%	-2.9%	-4.3%	-4.5%	-3.0%	-2.1%
Feb 17	HC Wainwright& Co.	Maintains	Buy → Buy	—	$491.47	$489.46	-0.4%	-2.9%	-4.3%	-4.5%	-3.0%	-2.1%
Feb 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$491.47	$489.46	-0.4%	-2.9%	-4.3%	-4.5%	-3.0%	-2.1%
Feb 17	Canaccord Genuity	Maintains	Hold → Hold	—	$491.47	$489.46	-0.4%	-2.9%	-4.3%	-4.5%	-3.0%	-2.1%
Feb 13	RBC Capital	Maintains	Outperform → Outperform	—	$465.02	$471.65	+1.4%	+5.7%	+2.6%	+1.1%	+0.9%	+2.6%
Feb 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$465.02	$471.65	+1.4%	+5.7%	+2.6%	+1.1%	+0.9%	+2.6%
Feb 13	Oppenheimer	Upgrade	Perform → Outperform	—	$465.02	$471.65	+1.4%	+5.7%	+2.6%	+1.1%	+0.9%	+2.6%
Feb 13	Scotiabank	Maintains	Sector Perform → Sector Perform	—	$465.02	$471.65	+1.4%	+5.7%	+2.6%	+1.1%	+0.9%	+2.6%
Feb 13	Stifel	Maintains	Hold → Hold	—	$465.02	$471.65	+1.4%	+5.7%	+2.6%	+1.1%	+0.9%	+2.6%
Jan 28	Barclays	Upgrade	Equal Weight → Overweight	—	$474.17	$474.09	-0.0%	+0.8%	+0.3%	-0.9%	-0.5%	-1.8%
Jan 26	UBS	Maintains	Buy → Buy	—	$468.41	$470.79	+0.5%	+1.8%	+1.2%	+2.0%	+1.6%	+0.3%
Jan 23	Evercore ISI	Maintains	Outperform → Outperform	—	$467.35	$465.23	-0.5%	+0.2%	+2.0%	+1.5%	+2.3%	+1.8%
Jan 22	RBC Capital	Upgrade	Sector Perform → Outperform	—	$461.14	$463.74	+0.6%	+1.3%	+1.6%	+3.4%	+2.8%	+3.6%
Jan 12	Bernstein	Upgrade	Market Perform → Outperform	—	$463.86	$461.07	-0.6%	-0.7%	-2.0%	-3.1%	-5.4%	-4.9%
Jan 6	Wolfe Research	Upgrade	Peer Perform → Outperform	—	$448.80	$454.85	+1.3%	+4.4%	+7.9%	+4.7%	+3.4%	+2.6%
Dec 29	Leerink Partners	Maintains	Outperform → Outperform	—	$462.90	$463.00	+0.0%	-0.7%	-2.0%	-2.1%	-2.3%	-3.0%
Dec 10	Wells Fargo	Maintains	Overweight → Overweight	—	$437.01	$438.81	+0.4%	+1.7%	+2.0%	+3.4%	+4.3%	+4.1%
Dec 5	Morgan Stanley	Maintains	Overweight → Overweight	—	$457.36	$457.78	+0.1%	-0.4%	-3.3%	-4.4%	-2.8%	-2.5%
Dec 3	Morgan Stanley	Upgrade	Equal Weight → Overweight	—	$433.15	$440.31	+1.7%	+6.9%	+5.6%	+5.2%	+2.1%	+0.9%
Nov 7	UBS	Maintains	Buy → Buy	—	$416.25	$415.61	-0.2%	-1.6%	+1.2%	+3.1%	+4.3%	+4.4%
Nov 4	Barclays	Maintains	Equal Weight → Equal Weight	—	$426.00	$418.55	-1.7%	-1.0%	-2.1%	-2.3%	-3.9%	-1.1%
Nov 4	Stifel	Maintains	Hold → Hold	—	$426.00	$418.55	-1.7%	-1.0%	-2.1%	-2.3%	-3.9%	-1.1%
Nov 4	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$426.00	$418.55	-1.7%	-1.0%	-2.1%	-2.3%	-3.9%	-1.1%
Oct 10	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$414.86	$413.33	-0.4%	-1.7%	-1.8%	-0.6%	-1.7%	-1.5%
Oct 8	JP Morgan	Maintains	Overweight → Overweight	—	$410.28	$410.93	+0.2%	+2.6%	+1.1%	-0.6%	-0.7%	+0.5%
Oct 2	Citigroup	Maintains	Buy → Buy	—	$404.21	$404.21	+0.0%	+1.1%	-0.2%	-0.3%	+1.5%	+4.2%
Sep 25	Leerink Partners	Upgrade	Market Perform → Outperform	—	$376.62	$383.20	+1.7%	+1.4%	+2.4%	+5.0%	+4.0%	+7.3%
Sep 11	Evercore ISI	Maintains	Outperform → Outperform	—	$388.55	$388.55	+0.0%	+2.3%	+1.5%	+1.2%	+0.7%	-0.4%
Aug 7	Citigroup	Maintains	Buy → Buy	—	$385.65	$385.00	-0.2%	-2.6%	-5.0%	-2.9%	+0.5%	+2.7%
Aug 6	Wells Fargo	Upgrade	Equal Weight → Overweight	—	$374.98	$375.76	+0.2%	+2.8%	+0.2%	-2.3%	-0.1%	+3.4%
Aug 6	Guggenheim	Maintains	Buy → Buy	—	$374.98	$375.76	+0.2%	+2.8%	+0.2%	-2.3%	-0.1%	+3.4%
Aug 6	Canaccord Genuity	Maintains	Hold → Hold	—	$374.98	$375.76	+0.2%	+2.8%	+0.2%	-2.3%	-0.1%	+3.4%
Aug 5	Scotiabank	Maintains	Sector Perform → Sector Perform	—	$472.27	$408.22	-13.6%	-20.6%	-18.3%	-20.5%	-22.4%	-20.7%
Aug 5	Truist	Maintains	Buy → Buy	—	$472.27	$408.22	-13.6%	-20.6%	-18.3%	-20.5%	-22.4%	-20.7%
Aug 5	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$472.27	$408.22	-13.6%	-20.6%	-18.3%	-20.5%	-22.4%	-20.7%
Aug 5	BMO Capital	Maintains	Outperform → Outperform	—	$472.27	$408.22	-13.6%	-20.6%	-18.3%	-20.5%	-22.4%	-20.7%
Aug 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$472.27	$408.22	-13.6%	-20.6%	-18.3%	-20.5%	-22.4%	-20.7%
Aug 5	UBS	Maintains	Buy → Buy	—	$472.27	$408.22	-13.6%	-20.6%	-18.3%	-20.5%	-22.4%	-20.7%
Aug 5	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$472.27	$408.22	-13.6%	-20.6%	-18.3%	-20.5%	-22.4%	-20.7%
Aug 5	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$472.27	$408.22	-13.6%	-20.6%	-18.3%	-20.5%	-22.4%	-20.7%
Aug 5	Stifel	Maintains	Hold → Hold	—	$472.27	$408.22	-13.6%	-20.6%	-18.3%	-20.5%	-22.4%	-20.7%

Recent Filings

8-K · 5.02 !!! Very High

Vertex Pharmaceuticals Inc -- 8-K 5.02: Executive Change

Vertex Pharmaceuticals appointed and simultaneously had Suketu Upadhyay resign as director, suggesting a potential leadership transition or restructuring that investors should monitor for strategic implications.

Apr 29

8-K · 8.01 !! High

Unknown — 8-K 8.01: Material Event / Announcement

VRTX's vague forward-looking statement caution suggests upcoming announcements may disappoint if projections don't materialize, warranting investor caution on stock volatility.

Mar 31

8-K · 8.01 !! High

Unknown — 8-K 8.01: Material Event / Announcement

Absci's rapid progression of AI-designed ABS-201 into human trials with positive safety signals validates its platform technology, potentially justifying higher valuations if clinical efficacy data continues to impress investors.

Mar 24

8-K

Vertex Pharmaceuticals Inc -- 8-K Filing

Vertex Pharmaceuticals expects accelerated FDA approval of povetacicept for IgAN in the first half of 2026, potentially adding a new revenue stream while the company advances its cystic fibrosis and gene therapy portfolios.

Feb 12

Data updated apr 27, 2026 8:11am · Source: massive.com